Stroke continues to be a leading cause of mortality and long-term disability worldwide, presenting significant challenges in prevention, acute intervention, and rehabilitation. While breakthroughs in reperfusion therapies (e.g., thrombolysis and thrombectomy) have achieved modest success, critical challenges persist in identifying stroke risk, reducing disability after stroke and lowering medical expenditures. The development of new neuroprotective technologies and the optimization of stroke disability reduction management plans are the keys to solving the problem. Recent genetic and multi-omics breakthroughs are revealing how inherited and molecular factors shape stroke risk, response to neuroprotective therapy, and recovery. Despite these advances, the translation of genetic and omics discoveries into routine clinical practice of stroke remains limited. Emerging applications—such as genome-wide association studies, polygenic risk scores, and multi-omics biomarker platforms—are now poised to revolutionize stroke management by enabling precision prevention and novel therapeutic strategies. We invite researchers and clinicians working at the stroke care, intersection of genomics, and omics technologies, to contribute original research, reviews, or clinical studies illustrating how these advances can directly improve patient outcomes.

This Research Topic seeks to address the critical gap between genetic and multi-omics discoveries in stroke and their clinical implementation. Our goal is to highlight recent advances in promoting the development of neuroprotective technologies, personalized stroke prevention, post-stroke disability reduction, and improved risk stratification by leveraging multi-omics data. We aim to showcase research that moves from understanding disease mechanisms to deploying omics-driven tools and strategies at the bedside, with particular interest in studies that inform neuroprotective therapies and novel interventions for reducing post-stroke disability. Submissions should emphasize clinically actionable insights and novel translational approaches that bridge the divide between scientific innovation and real-world stroke management, as well as those that contribute to the development or optimization of neuroprotective or disability-reducing management paradigms.

We invite submissions that span the translational spectrum of stroke research, with a focus on clinically relevant genetic and multi-omics innovations particularly in neuroprotection strategies and disability reduction approaches. Relevant themes include, but are not limited to:
• Omics-driven stroke risk prediction using polygenic risk scores, GWAS, or rare variant analyses.
• Genotype-guided therapeutic approaches, such as pharmacogenomics and targeted interventions, especially those aimed at acute neuroprotection or long-term functional recovery.
• Identification and validation of multi-omics biomarkers for diagnosis, prognosis, neuroprotection efficacy evaluation, and continuous patient monitoring in stroke.
• Clinical trials, real-world studies, and reviews that demonstrate the efficacy of neuroprotection strategies and disability reduction approaches
• Population-based studies addressing disparities and the generalizability of genetic findings.
• Machine learning and artificial intelligence applications in omics data integration and patient stratification, particularly for identifying candidates who may benefit from neuroprotective interventions or tailored rehabilitation.
• Ethical and societal considerations regarding the clinical use of omics data in stroke and neuroprotection.

We welcome Original Research, Reviews, Clinical Trials, and Methodological papers that advance the integration of genetics and omics into stroke care. Contributions illustrating innovative links between genomics, emerging technology, and clinical benefit are especially encouraged.

Are you interested in contributing a manuscript to this Research Topic?

Genetic and Multi-Omics Advances in Stroke Management: From Mechanism to Real-World Clinical Translation